Rubius Therapeutics Banner Image

Rubius Therapeutics

  • Ticker RUBY
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Rubius Therapeutics Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Their proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Their initial focus is to advance RCT™ productMore candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. They plan to file their first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. They are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond.
4.8 / 5.0 (132)

Rubius Therapeutics reports have an aggregate usefulness score of 4.8 based on 132 reviews.

Rubius Therapeutics

Most Recent Annual Report

Rubius Therapeutics
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports

Rubius Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!